BidaskClub downgraded shares of Heska (NASDAQ:HSKA) from a buy rating to a hold rating in a report issued on Thursday, November 8th.
Other analysts also recently issued research reports about the stock. Benchmark started coverage on shares of Heska in a research report on Thursday, July 19th. They set a buy rating and a $120.00 price objective for the company. TheStreet downgraded shares of Heska from a b rating to a c+ rating in a research report on Monday, August 20th. ValuEngine downgraded shares of Heska from a buy rating to a hold rating in a research report on Monday, July 30th. Finally, Zacks Investment Research raised shares of Heska from a strong sell rating to a hold rating in a research report on Wednesday, July 18th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. The company has an average rating of Hold and a consensus target price of $107.50.
Heska stock traded up $0.06 during mid-day trading on Thursday, hitting $103.98. 46,559 shares of the stock were exchanged, compared to its average volume of 32,311. The firm has a market cap of $789.13 million, a price-to-earnings ratio of 50.23 and a beta of 0.73. Heska has a 12 month low of $56.59 and a 12 month high of $114.50.
Heska (NASDAQ:HSKA) last announced its quarterly earnings data on Tuesday, November 6th. The medical research company reported $0.46 EPS for the quarter, topping the consensus estimate of $0.35 by $0.11. The company had revenue of $30.96 million during the quarter, compared to the consensus estimate of $31.14 million. Heska had a net margin of 1.01% and a return on equity of 11.48%. Equities research analysts expect that Heska will post 1.74 EPS for the current fiscal year.
In other Heska news, COO Jason A. Napolitano sold 2,500 shares of Heska stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $111.50, for a total transaction of $278,750.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Kevin S. Wilson sold 3,190 shares of Heska stock in a transaction on Friday, November 9th. The stock was sold at an average price of $104.07, for a total transaction of $331,983.30. Following the transaction, the chief executive officer now directly owns 106,810 shares in the company, valued at $11,115,716.70. The disclosure for this sale can be found here. In the last three months, insiders sold 16,321 shares of company stock valued at $1,711,425. 14.70% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HSKA. Dimensional Fund Advisors LP raised its stake in shares of Heska by 4.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 191,044 shares of the medical research company’s stock worth $15,106,000 after purchasing an additional 8,513 shares during the period. Millennium Management LLC raised its stake in shares of Heska by 715.5% during the 1st quarter. Millennium Management LLC now owns 29,357 shares of the medical research company’s stock worth $2,321,000 after purchasing an additional 25,757 shares during the period. Principal Financial Group Inc. raised its stake in shares of Heska by 2.4% during the 1st quarter. Principal Financial Group Inc. now owns 49,975 shares of the medical research company’s stock worth $3,952,000 after purchasing an additional 1,162 shares during the period. Raymond James Trust N.A. bought a new stake in shares of Heska during the 2nd quarter worth $240,000. Finally, Summit Creek Advisors LLC raised its stake in shares of Heska by 14.2% during the 2nd quarter. Summit Creek Advisors LLC now owns 71,868 shares of the medical research company’s stock worth $7,459,000 after purchasing an additional 8,915 shares during the period. Institutional investors own 85.87% of the company’s stock.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
Featured Article: Stock Symbols Definition, Examples, Lookup